Showing 8161-8170 of 8693 results for "".
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- FDA Approves Inflectra, a Biosimilar to Remicadehttps://practicaldermatology.com/news/fda-approves-inflectra-a-biosimilar-to-remicade/2458618/And then there were two ... The U.S. Food and Drug Administration approved the biosimilar Inflectra (infliximab-dyyb) for multiple indications. Inflectra is biosimilar to Janssen Biotech, Inc.&rsq
- Melanoma Cells Grow More Aggressive with Agehttps://practicaldermatology.com/news/melanoma-cells-grow-more-aggressive-with-age/2458622/Aged tumor cells in melanoma tend to be metastatic and more resistant to treatment compared with younger tumor cells, according to an international team led by researchers out of The Wistar Institute in Philadelphia. The findings, which appear in
- Galderma, Mentor Worldwide, LLC Set to Collaboratehttps://practicaldermatology.com/news/galderma-mentor-worldwide-llc-set-to-collaborate/2458623/Galderma and Mentor Worldwide LLC, are joining forces to increase awareness and provide a broader range of offerings to healthcare providers and patients seeking aesthetic injectable treatments and breast enhancement. Data shows up to 33% of women
- Tissue Regeneration Leader Takes Home 2016 Furumoto Award at ASLMS 2016https://practicaldermatology.com/news/tissue-regeneration-leader-takes-home-2016-furumoto-award-at-aslms-2016/2458627/Praveen Arany, DDS, PhD will receive the 2016 ASLMS Dr. Horace Furumoto Innovations Young Investigator Award during the Plenary Session at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS).
- Profounda Launches Impavido for Visceral, Mucosal and Cutaneous Leishmaniasishttps://practicaldermatology.com/news/profounda-launches-impavido-for-visceral-mucosal-and-cutaneous-leishmaniasis/2458636/Profounda, Inc. launched Impavido (miltefosine) in the United States. Impavido is the first oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the FDA and the first Rx product launched in the US by Profounda. Although skin sores of cutaneous leishmaniasis (CL) us
- Valeant Announces CEO Succession Plan And Changes To Board; Provides Accounting And Financial Reporting Updatehttps://practicaldermatology.com/news/valeant-announces-ceo-succession-plan-and-changes-to-board-provides-accounting-and-financial-reporting-update/2458640/Valeant’s board has initiated a search to identify a candidate to succeed J. Michael Pearson as chief executive officer (CEO). Mr. Pearson will continue to serve as CEO and a director until his replacement is appointed. The company also announced that William A. Ackman, CEO of Persh
- FDA Proposes Ban on Most Powdered Medical Gloveshttps://practicaldermatology.com/news/fda-proposes-ban-on-most-powdered-medical-gloves/2458639/The FDA has proposed a ban on most powdered gloves in the United States. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care providers, patients and other individuals who are exposed to them, which cannot be corrected t
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- FDA Approves PMA Supplement for MelaFind from STRATA Scienceshttps://practicaldermatology.com/news/fda-accepts-pma-for-melafind-from-strata-sciences/2458644/The FDA has approved STRATA Skin Sciences, Inc.’s PMA supplement for the MelaFind System. The FDA approved MelaFind’s use of the “classifier score data”, a quantitative result derived by the MelaFind System that can be beneficially used in conjunction with the previously a